PMID- 30281991
OWN - NLM
STAT- MEDLINE
DCOM- 20181005
LR  - 20181017
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 14
DP  - 2018 Oct 4
TI  - Cabozantinib in Hepatocellular Carcinoma.
PG  - 1384-1385
LID - 10.1056/NEJMc1810178 [doi]
FAU - Abou-Alfa, Ghassan K
AU  - Abou-Alfa GK
AD  - Memorial Sloan Kettering Cancer Center, New York, NY abou-alg@mskcc.org
FAU - Borgman-Hagey, Anne E
AU  - Borgman-Hagey AE
AD  - Exelixis, Alameda, CA
FAU - Kelley, Robin K
AU  - Kelley RK
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
SB  - AIM
SB  - IM
CON - N Engl J Med. ;379(14):1384. PMID: 30285325
MH  - Anilides
MH  - Antineoplastic Agents
MH  - *Carcinoma, Hepatocellular
MH  - Humans
MH  - *Liver Neoplasms
MH  - Protein Kinase Inhibitors
MH  - Pyridines
EDAT- 2018/10/04 06:00
MHDA- 2018/10/06 06:00
CRDT- 2018/10/04 06:00
PHST- 2018/10/04 06:00 [entrez]
PHST- 2018/10/04 06:00 [pubmed]
PHST- 2018/10/06 06:00 [medline]
AID - 10.1056/NEJMc1810178 [doi]
AID - 10.1056/NEJMc1810178#SA2 [pii]
PST - ppublish
SO  - N Engl J Med. 2018 Oct 4;379(14):1384-1385. doi: 10.1056/NEJMc1810178.